← All trials
NCT04667780
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2020
- Primary completion
- May 9, 2021
- Completion date
- Jul 9, 2021
- First posted
- Dec 16, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ayub Medical College, AbbottabadLead sponsor
- Universidad de MurciaCollaborator
- Ayub Medical College, AbbottabadReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.